DRUG vs. ^GSPC

Last updated Apr 2, 2026

Compare and contrast key facts about Bright Minds Biosciences Inc (DRUG) and S&P 500 Index (^GSPC).

Performance

DRUG vs. ^GSPC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bright Minds Biosciences Inc (DRUG) and S&P 500 Index (^GSPC). The values are adjusted to include any dividend payments, if applicable.

DRUG vs. ^GSPC - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
DRUG Bright Minds Biosciences Inc	-8.10%	116.66%	2,418.88%	-61.35%	-76.66%	-41.30%
^GSPC S&P 500 Index	-3.95%	16.39%	23.31%	24.23%	-19.44%	20.95%

Returns By Period

In the year-to-date period, DRUG achieves a -8.10% return, which is significantly lower than ^GSPC's -3.95% return.

DRUG

• 1D: -1.71%
• 1M: -13.39%
• YTD: -8.10%
• 6M: 23.76%
• 1Y: 98.62%
• 3Y*: 219.43%
• 5Y*: 21.80%
• 10Y*: —

^GSPC

• 1D: 0.72%
• 1M: -4.45%
• YTD: -3.95%
• 6M: -2.02%
• 1Y: 16.73%
• 3Y*: 16.96%
• 5Y*: 10.34%
• 10Y*: 12.24%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

DRUG vs. ^GSPC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DRUG

DRUG Risk / Return Rank: 80
DRUG Sharpe Ratio Rank: 80
DRUG Sortino Ratio Rank: 82
DRUG Omega Ratio Rank: 73
DRUG Calmar Ratio Rank: 83
DRUG Martin Ratio Rank: 80

^GSPC

^GSPC Risk / Return Rank: 67
^GSPC Sharpe Ratio Rank: 63
^GSPC Sortino Ratio Rank: 64
^GSPC Omega Ratio Rank: 69
^GSPC Calmar Ratio Rank: 60
^GSPC Martin Ratio Rank: 77

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DRUG vs. ^GSPC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Bright Minds Biosciences Inc (DRUG) and S&P 500 Index (^GSPC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DRUG	^GSPC	Difference
Sharpe ratio Return per unit of total volatility	1.34	0.92	+0.42
Sortino ratio Return per unit of downside risk	2.24	1.41	+0.82
Omega ratio Gain probability vs. loss probability	1.24	1.21	+0.03
Calmar ratio Return relative to maximum drawdown	2.78	1.41	+1.36
Martin ratio Return relative to average drawdown	6.19	6.61	-0.43
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DRUG vs. ^GSPC - Sharpe Ratio Comparison

The current DRUG Sharpe Ratio is 1.34, which is higher than the ^GSPC Sharpe Ratio of 0.92. The chart below compares the historical Sharpe Ratios of DRUG and ^GSPC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	DRUG	^GSPC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.34	0.92	+0.42
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.03	0.61	-0.58
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.68	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.03	0.46	-0.43

Correlation

The correlation between DRUG and ^GSPC is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Drawdowns

DRUG vs. ^GSPC - Drawdown Comparison

The maximum DRUG drawdown since its inception was -97.68%, which is greater than ^GSPC's maximum drawdown of -56.78%. Use the drawdown chart below to compare losses from any high point for DRUG and ^GSPC.

Drawdown Indicators

	DRUG	^GSPC	Difference
Max Drawdown Largest peak-to-trough decline	-97.68%	-56.78%	-40.90%
Max Drawdown (1Y) Largest decline over 1 year	-34.10%	-12.14%	-21.96%
Max Drawdown (5Y) Largest decline over 5 years	-97.68%	-25.43%	-72.25%
Max Drawdown (10Y) Largest decline over 10 years	—	-33.92%	—
Current Drawdown Current decline from peak	-25.28%	-5.78%	-19.50%
Average Drawdown Average peak-to-trough decline	-60.63%	-10.75%	-49.88%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.97%	2.60%	+13.37%

Volatility

DRUG vs. ^GSPC - Volatility Comparison

Bright Minds Biosciences Inc (DRUG) has a higher volatility of 13.61% compared to S&P 500 Index (^GSPC) at 5.37%. This indicates that DRUG's price experiences larger fluctuations and is considered to be riskier than ^GSPC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DRUG	^GSPC	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.61%	5.37%	+8.24%
Volatility (6M) Calculated over the trailing 6-month period	49.40%	9.55%	+39.85%
Volatility (1Y) Calculated over the trailing 1-year period	74.18%	18.33%	+55.85%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	662.78%	16.90%	+645.88%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	660.68%	18.05%	+642.63%